Skip to Main Content

2,818

Views

6

CrossRef citations to date

0

Altmetric

Original Research

A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)

Christopher Wynnea New Zealand Clinical Research, Christchurch, New ZealandView further author information

,

Christian Schwabeb New Zealand Clinical Research, Auckland, New ZealandView further author information

,

Charlotte Lemechc Scientia Clinical Research, NSW, AustraliaView further author information

,

Heimo Stroissnigd Alvotech Germany GmbH, Jülich, GermanyView further author information

,

Roshan Diase Alvotech Swiss AG, Zürich, SwitzerlandView further author information

,

Joanna Sobierskae Alvotech Swiss AG, Zürich, SwitzerlandView further author information

,

Eric Guenzid Alvotech Germany GmbH, Jülich, GermanyView further author information

,

Hendrik Ottod Alvotech Germany GmbH, Jülich, GermanyView further author information

,

Abid Sattarf Alvotech UK Ltd, London, UKView further author information

,

Richard Kayg RK Statistics Ltd, Bakewell, UKView further author information

,

Halimu N. Haliduolad Alvotech Germany GmbH, Jülich, GermanyView further author information

&

Fausto Bertie Alvotech Swiss AG, Zürich, SwitzerlandCorrespondence[email protected]
View further author information